Skip to main content
. 2013 Aug 20;104(10):1346–1352. doi: 10.1111/cas.12237

Figure 3.

Figure 3

Antitumor activity of CH5164840 in combination with erlotinib on NCI‐H292 EGFR‐overexpressing NSCLC in vitro and in vivo. (a,b) NCI‐H292 cells were treated with 0.2 μM erlotinib and/or 0.5 μM CH5164840 for 48 h (for caspase‐3/7 activity and cell viability) and 96 h (for cell viability). Caspase‐3/7 activity and cell viability were measured with the Caspase‐Glo 3/7 assay and CellTiter‐Glo, respectively, using EnVision High Throughput Screening. Caspase‐3/7 activity was normalized to cell viability. (c) Mice bearing NCI‐H292 tumors were orally administered 12.5 mg/kg CH5164840 daily for 11 consecutive days and/or 25 mg/kg erlotinib. Tukey's test: ***P < 0.001.